0 items USD 0.00Search
Your search for "hjresearch global hemophilia b recombinant factor replacement therapy industry market research" gave back 758464 results.
The global Recombinant Protein Drug R & D market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a...
Catalog:
MRRPB5
February 2024
Price: USD 2,900.00
The global Bleeding Disorders market size was valued at US$ 10580 million in 2023. With growing demand in downstream market, the Bleeding Disorders...
Catalog:
LPI
March 2024
Price: USD 3,660.00
The global Recombinant Human Coagulation VIIa market size was valued at USD 1166.6 million in 2023 and is forecast to a readjusted size of USD 1488.4...
Catalog:
GIR
January 2024
Price: USD 3,480.00
Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8...
Catalog:
MRRPB5
March 2024
Price: USD 2,900.00
The bleeding disorder is a condition in which there is a problem associated with the normal blood clotting process in the body, which gets affected...
Catalog:
MRRPB5
January 2024
Price: USD 2,900.00
Coagulation Factor VIIa, recombinant is a coagulation factor indicated for: Treatment of bleeding episodes and perioperative management in adults and...
Catalog:
MRRPB5
October 2023
Price: USD 2,900.00
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this...
Catalog:
MRRPB5
February 2024
Price: USD 2,900.00
The global Recombinant Human Coagulation VIIa market size was valued at US$ 1109.1 million in 2023. With growing demand in downstream market, the...
Catalog:
LPI
January 2024
Price: USD 3,660.00
Recombinant human growth hormone is produced by gene recombinant Escherichia coli secretory expression technology, and it is completely consistent...
Catalog:
MRRPB5
October 2023
Price: USD 2,900.00
Coagulation Factor VIIa, recombinant is a coagulation factor indicated for: Treatment of bleeding episodes and perioperative management in adults and...
Catalog:
MRRPB5
July 2023
Price: USD 4,900.00
The recombinant antihemophilic globulin is a drug synthesized by gene recombination technology, which is used to treat patients with hemophilia A...
Catalog:
MRRPB5
September 2023
Price: USD 2,900.00
For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation...
Catalog:
MRRPB5
February 2024
Price: USD 2,900.00
The global Hemophilia Treatment Drugs market size was valued at US$ 10590 million in 2023. With growing demand in downstream market, the Hemophilia...
Catalog:
LPI
March 2024
Price: USD 3,660.00
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this...
Catalog:
MRRPB5
May 2023
Price: USD 2,900.00
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it...
Catalog:
MRRPB5
October 2023
Price: USD 2,900.00
